BACKGROUND: We sought to determine the minimum survival benefits that patients judged sufficient to make adjuvant chemotherapy for early colon cancer worthwhile, factors associated with these judgments; and, to compare a self-administered questionnaire with a validated, scripted interview. PATIENTS AND METHODS: One twenty three subjects who completed adjuvant chemotherapy for early colon cancer 3-60 months earlier completed a questionnaire; 97 were randomised to complete an interview before or after the questionnaire. Preferences were elicited by the time trade-off method in 4 hypothetical scenarios. Concordance between the interview and questionnaire was assessed with the intraclass correlation coefficient (ICC). RESULTS: Median age was 65 years (range 19-86), 52% were female and 74% had involved lymph nodes. Over 60% of patients judged an additional 1 month beyond life expectancies of 5 years or 15 years, and an additional 1-2% beyond 5-year survival rates of 85% or 65%, sufficient to make chemotherapy worthwhile. Subjects with tertiary education (p=0.003) or aged 75 years or less (p=0.02) judged larger benefits necessary to make chemotherapy worthwhile. Concordance between the interview and questionnaire was high (ICCs 0.71-0.82). CONCLUSIONS: Most subjects judged small survival benefits sufficient to make adjuvant chemotherapy worthwhile. A self-administered questionnaire was a valid and acceptable way of eliciting preferences. Copyright 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: We sought to determine the minimum survival benefits that patients judged sufficient to make adjuvant chemotherapy for early colon cancer worthwhile, factors associated with these judgments; and, to compare a self-administered questionnaire with a validated, scripted interview. PATIENTS AND METHODS: One twenty three subjects who completed adjuvant chemotherapy for early colon cancer 3-60 months earlier completed a questionnaire; 97 were randomised to complete an interview before or after the questionnaire. Preferences were elicited by the time trade-off method in 4 hypothetical scenarios. Concordance between the interview and questionnaire was assessed with the intraclass correlation coefficient (ICC). RESULTS: Median age was 65 years (range 19-86), 52% were female and 74% had involved lymph nodes. Over 60% of patients judged an additional 1 month beyond life expectancies of 5 years or 15 years, and an additional 1-2% beyond 5-year survival rates of 85% or 65%, sufficient to make chemotherapy worthwhile. Subjects with tertiary education (p=0.003) or aged 75 years or less (p=0.02) judged larger benefits necessary to make chemotherapy worthwhile. Concordance between the interview and questionnaire was high (ICCs 0.71-0.82). CONCLUSIONS: Most subjects judged small survival benefits sufficient to make adjuvant chemotherapy worthwhile. A self-administered questionnaire was a valid and acceptable way of eliciting preferences. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Barbara K Bennett; Susanna B Park; Cindy S-Y Lin; Michael L Friedlander; Matthew C Kiernan; David Goldstein Journal: Support Care Cancer Date: 2012-03-17 Impact factor: 3.603
Authors: Steven R Alberts; Tiffany M Yu; Robert J Behrens; Lindsay A Renfro; Geetika Srivastava; Gamini S Soori; Shaker R Dakhil; Rex B Mowat; John P Kuebler; George P Kim; Miroslaw A Mazurczak; John Hornberger Journal: Pharmacoeconomics Date: 2014-12 Impact factor: 4.981
Authors: Prunella Blinman; Linda Mileshkin; Pearly Khaw; Geraldine Goss; Carol Johnson; Anne Capp; Susan Brooks; Gerard Wain; Ilka Kolodziej; Anne-Sophie Veillard; Rachel O'Connell; Carien L Creutzberg; Martin R Stockler Journal: Br J Cancer Date: 2016-10-20 Impact factor: 7.640
Authors: Juan Marcos González; Sarika Ogale; Robert Morlock; Joshua Posner; Brett Hauber; Nicolas Sommer; Axel Grothey Journal: Cancer Manag Res Date: 2017-04-27 Impact factor: 3.989